Pulmonx
Gabriel M. Brown is a seasoned health economist with extensive experience in health economics, reimbursement, and public policy. Currently serving as Senior Manager for Health Economics & Reimbursement at Pulmonx Corporation since August 2022, Gabriel previously held the position of Director of Real World Evidence at Science 37 and Senior Health Economist for North America at AMBU INC. - USA. Gabriel has demonstrated strong leadership in various roles, guiding health economics and outcomes research initiatives while managing teams. Academic credentials include a Master’s Degree in Health Policy and Management, along with multiple graduate certificates, all obtained from the Johns Hopkins Bloomberg School of Public Health, and a Bachelor's Degree in Political Science from Virginia Tech.
This person is not in any offices
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1